The following represents disclosure information provided by authors of this abstract. The Gastrointestinal Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Effect of the addition of algenpantucel-L immunotherapy to standard adjuvant therapy on survival in patients with resected pancreas cancer.
Jeffrey M Hardacre
Disclosure not yet available
Mary Frances Mulcahy
Disclosure not yet available
William Small
Disclosure not yet available
Mark Talamonti
Disclosure not yet available
Jennifer Carrie Obel
Disclosure not yet available
Caio Max S. Rocha Lima
Disclosure not yet available
Howard Safran
Disclosure not yet available
Heinz-Josef Lenz
Disclosure not yet available
Elena G. Chiorean
Disclosure not yet available
Charles J. Link
Disclosure not yet available